Preston D. Steen

机构：Fargo VA Health Care System · ORCID：0000-0003-3474-9098

发表论文 57 篇 · 总被引 1895 次 · h-index 21

代表论文

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer (2022 · Annals of Oncology · 被引 463)
• Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire (2013 · Quality of Life Research · 被引 201)
• Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial (2016 · The Lancet Oncology · 被引 134)
• A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes (2011 · Menopause The Journal of The North American Menopause Society · 被引 76)
• Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance) (2015 · Annals of Oncology · 被引 57)
• A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621 (2014 · Lung Cancer · 被引 44)